IRONWOOD PHARMACEUTICALS, INC. Net Change in Cash
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Net Change in Cash of -$136.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $5.01M, a 74.83% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $19.92M, a 32.21% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $29.39M, a 65.07% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $84.14M.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $126.90M.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$3.60M.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$565.78M, a 1668.40% decline from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $36.07M, a 85.97% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$136.33M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $5.01M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $126.90M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $51.85M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $4.29M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $19.92M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$3.60M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$3.94M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $13.37M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $29.39M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$565.78M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$546.48M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$481.32M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $84.14M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $36.07M 10-K · filed 2025-03-31 | |||
| 2022-09-30 | -$45.94M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$115.76M 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | -$26.76M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $257.08M 10-K · filed 2024-02-16 | |||
| 2021-09-30 | $211.23M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $130.13M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $75.91M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $185.54M 10-K · filed 2023-02-16 | |||
| 2020-09-30 | $130.53M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $76.23M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $54.12M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$1.60M 10-K · filed 2022-02-18 | |||
| 2019-09-30 | -$32.97M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$73.29M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$54.13M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $48.06M 10-K · filed 2021-02-17 | |||
| 2018-09-30 | $16.45M 10-Q · filed 2019-10-31 | |||
| 2018-06-30 | $20.93M 10-Q · filed 2019-07-30 | |||
| 2018-03-31 | $19.05M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $70.54M 10-K · filed 2020-02-13 | |||
| 2017-09-30 | $107.45M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $126.94M 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | $79.31M 10-Q · filed 2018-05-04 | |||
| 2016-12-31 | -$207.78M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |